8 days ago
LLY
AnalystsSeamus FernandezSeamus Fernandez's Stock Forecasts
AnalystsSeamus Fernandez
Analyst Ranking
Top 5%
#212 out of 5064 analysts
Average Return
+40.72%
Win Rate
62%40 out of 65
Risk vs Reward
Poor
Good
Seamus Fernandez's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Cidara Therapeutics IncCDTX | +682.37% | $13.50 | $105.62 | 2024-11-08 - 2025-10-15 | Strong Buy |
Cidara Therapeutics IncCDTX | +466.94% | $18.63 | $105.62 | 2025-05-09 - 2025-10-15 | Strong Buy |
Cidara Therapeutics IncCDTX | +314.20% | $25.50 | $105.62 | 2025-05-16 - 2025-10-15 | Strong Buy |
Amylyx Pharmaceuticals IncAMLX | +146.33% | $6.41 | $15.79 | 2025-06-24 - 2025-10-15 | Strong Buy |
Albireo Pharma IncALBO | +142.18% | $18.23 | $44.15 | 2022-09-08 - 2023-03-02 | Strong Buy |
Seamus Fernandez Analyst Color
Get additional color on Seamus Fernandez's coverage of popular stocks
21 days ago
CDTX
23 days ago
MBX
a month ago
AMLX
4 months ago
CDTX
5 months ago
CDTX
5 months ago
CDTX
6 months ago
LLY
a year ago
APGE
a year ago
LLY
2 years ago
APGE
2 years ago
APGE
3 years ago
MRK
3 years ago
LLY
4 years ago
MRK
Seamus Fernandez's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Eli Lilly & CoLLY | 11 | Strong Buy | $948.00 | +14.69% | Maintains | 8 days ago |
Cidara Therapeutics IncCDTX | 5 | Strong Buy | $167.00 | +58.11% | Maintains | 21 days ago |
Mbx Biosciences IncMBX | 3 | Strong Buy | $84.00 | +502.15% | Maintains | 23 days ago |
Amylyx Pharmaceuticals IncAMLX | 2 | Strong Buy | $25.00 | +58.33% | Maintains | a month ago |
Tenax Therapeutics IncTENX | 2 | Strong Buy | $14.00 | +100.57% | Maintains | 2 months ago |
Structure Therapeutics IncGPCR | 2 | Strong Buy | $90.00 | +207.90% | Maintains | 2 months ago |
Rhythm Pharmaceuticals IncRYTM | 2 | Strong Buy | $120.00 | +9.74% | Maintains | 2 months ago |
Apogee Therapeutics IncAPGE | 6 | Strong Buy | $116.00 | +107.70% | Reiterates | 3 months ago |
Vaxcyte IncPCVX | 4 | Strong Buy | $160.00 | +264.13% | Reiterates | 7 months ago |
Metsera IncMTSR | 1 | Strong Buy | $56.00 | +6.10% | Initiates Coverage On | 8 months ago |
Merck & Co IncMRK | 9 | Strong Buy | $122.00 | +45.05% | Maintains | 9 months ago |
Icosavax IncICVX | 1 | Strong Buy | $28.00 | N/A | Initiates Coverage On | 2 years ago |
Hillevax IncHLVX | 2 | Strong Buy | $34.00 | N/A | Maintains | 2 years ago |
Verve Therapeutics IncVERV | 1 | Strong Buy | $55.00 | N/A | Maintains | 2 years ago |
Cymabay Therapeutics IncCBAY | 1 | Strong Buy | $20.00 | N/A | Initiates Coverage On | 2 years ago |
Arcturus Therapeutics Holdings IncARCT | 1 | Strong Buy | $36.00 | N/A | Reiterates | 3 years ago |
Mineralys Therapeutics IncMLYS | 1 | Strong Buy | $32.00 | N/A | Initiates Coverage On | 3 years ago |
Dice Therapeutics IncDICE | 1 | Strong Buy | $65.00 | N/A | Initiates Coverage On | 3 years ago |
Bristol Myers Squibb CoBMY | 5 | Hold | N/A | N/A | Downgrades | 3 years ago |
Altimmune IncALT | 2 | Strong Buy | $26.00 | N/A | Maintains | 3 years ago |
Albireo Pharma IncALBO | 1 | Strong Buy | $55.00 | N/A | Initiates Coverage On | 3 years ago |
Invivyd IncIVVD | 2 | Hold | N/A | N/A | Downgrades | 4 years ago |
Novartis AgNVS | 3 | Hold | N/A | N/A | Downgrades | 6 years ago |
Dermira IncDERM2 | 1 | Hold | N/A | N/A | Downgrades | 6 years ago |
Tesaro IncTSRO | 4 | Hold | $75.00 | N/A | Downgrades | 7 years ago |
Intra Cellular Therapies IncITCI | 3 | Buy | $27.00 | N/A | Initiates Coverage On | 7 years ago |
Allergan PLCAGN | 3 | Buy | $220.00 | N/A | Initiates Coverage On | 7 years ago |
Aclaris Therapeutics IncACRS | 1 | Buy | $54.00 | N/A | Maintains | 8 years ago |
Celldex Therapeutics IncCLDX | 2 | Hold | $45.00 | N/A | Maintains | 8 years ago |
Astrazeneca PLCAZN | 2 | Hold | $38.00 | N/A | Maintains | 8 years ago |
Pfizer IncPFE | 1 | Hold | $38.00 | N/A | Maintains | 8 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.